<DOC>
	<DOCNO>NCT01984073</DOCNO>
	<brief_summary>The purpose study understand whether vitamin call NIcotinic ACid vitamIN ( NIACIN short , also know vitamin B3 ) help body process dietary fat efficiently . This important people dyslipidemia problem process fat , raise risk heart disease .</brief_summary>
	<brief_title>Effects Niacin On Fatty Acid Trapping</brief_title>
	<detailed_description>This study include three phase , separate purpose . At time , recruit Phase 2 . The purpose particular phase measure effect niacin drink glass heavy cream source fat . We hope study way body respond help u good understand niacin work . In study , interested niacin 's ability lower triglyceride , fat blood . We study two different form niacin compare . The two form differ long take release niacin bloodstream . The first form call Nialor , sometimes call immediate-release niacin absorb bloodstream quickly . The second form call Niaspan , sometimes call extended-release niacin time-released spansule take long get bloodstream . We compare two form think time take absorb niacin may affect work . We also want understand one common effect niacin : skin flushing . Most people take niacin experience flushing , hot flash . In study , study whether two form niacin cause different degree flush . Niaspan approve US Food Drug Administration ( FDA ) treat unfavorable cholesterol level prevent heart attack already suffer heart attack . Nialor available counter supplement contain Silymarin ( milk thistle ) Policosanol ( extract sugar cane ) addition niacin .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Meet protocol define criterion atherogenic dyslipidemia phenotype Men nonpregnant , nonlactating woman age 22 75 Fasting triglyceride &lt; 500 mg/dL Ability understand agree inform consent Willingness comply studyrelated procedure Dysbetalipoproteinemia History extreme triglyceridemia ( TG &gt; 500 mg/dL ) pancreatitis triglyceridemia , regardless whether currently control LDL &gt; 190 mg/dL History chronic renal insufficiency ( serum creatinine &gt; 2.0 mg/dL ) History nonskin malignancy within previous 5 year Subject report history HIV Uncontrolled thyroid disease Hypoalbuminemia ( serum albumin &gt; 2.5 mg/dL ) Exposure investigational drug within 6 week prior screen visit Any major active rheumatologic , pulmonary , dermatologic disease inflammatory condition Major surgery within previous 6 week Subjects undergone organ transplant History drug abuse within past 3 year , regular alcohol use &gt; 14 drink per week Women breastfeed Women pregnant urine pregnancy test visit Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study Change statin dose within 6 week first experimental visit Use follow nonstatin lipidaltering therapy within 6 week first experimental visit : Niacin &gt; 100 mg/day ( Niacor , SloNiacin , Niaspan , Advicor , supplemental niacin ) , Fibrates [ gemfibrozil ( Lopid ) , fenofibrate ( Antara , Lofibra , Tricor , Triglide ) ] , Enterically active drug [ colestipol ( Colestid ) , cholestyramine ( Questran ) , colesevelam ( Welchol ) , ezetimibe ( Zetia , Vytorin ) ] , Red yeast rice , Fish oil ( Omacor , numerous supplement ) Use medication indicate treatment diabetes within 6 week screen visit Known intolerance contraindication niacin ( e.g. , moderate severe gout , severe peptic ulcer disease ) Medical condition would prohibit fasting ( e.g. , diagnosis insulinoma postabsorptive hypoglycemia ) Significant disinclination dairy product ( e.g. , lactose intolerance , inviolable dietary restriction ) History anaphylactic reaction For indocyanine green substudy : iodine allergy shellfish allergy ( n.b . subject allergy participate overall experiment , forego indocyanine green tracer study ) Donation blood 8 week and/or treatment medication psychiatric disorder Hemoglobin &lt; 10 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Atherogenic dyslipidemia phenotype</keyword>
</DOC>